Validation of proposals for definitions of moderate and severe disease activity in SLE: impact on flares, quality of life, damage accrual, hospitalisations and mortality Authors: Irene Altabás-González, Iñigo Rua-Figueroa, Karen Roberts, Ivonne Lourdes Mamani, Coral Mouriño, Julia Martinez-Barrio, Maria Galindo Izquierdo, Jaime Calvo-Alén, Celia Erausquin, Belén Serrano-Benavente, Esther Uriarte, Eva Tomero, Mercedes Freire-González, Ricardo Blanco, Eva Salgado, Silvia Gómez-Sabater, Antonio Fernandez-Nebro, Clara Sangüesa, Javier Narvaez, Natalia Mena Vázquez, Raúl Menor-Almagro, José Carlos Rosas Gómez de Salazar, Elena Aurrecoechea, Oihane Ibarguengoitia-Barrena, Carlos Montilla, Gema Bonilla, Vicente Torrente Segarra, Antonio Juan-Mas, María Jesús García-Villanueva, Claudia Moriano Morales, Loreto Horcada, Nuria Lozano-Rivas, Carlota Iñiguez, Marta Arevalo, Beatriz Paredes, Lorena Exposito, Francisco J Toyos, Eduardo Flores-Fernandez, Javier Nóvoa Medina, Jorge Juan Fragio Gil Published: 2025 ABSTRACT AbstractIntroductionAccurate assessment of disease activity in SLE is crucial but challenging due to its varied clinical manifestations and severity. Current tools like the SLE Disease Activity Index (SLEDAI) have limitations, including unvalidated cut-off points, low sensitivity to certain severe features and an overemphasis on serological markers. There is a need for improved definitions of disease activity.MethodsWe analysed data from 1463 patients with SLE in the prospective, multicentre RELESSER-PROS cohort (39 Spanish hospitals) over five annual visits. A panel of lupus experts used the Delphi method to develop new definitions for moderate disease activity state (MODAS) and severe disease activity state (SEDAS). These incorporated clinical SLEDAI (cSLEDAI), selected severe non-SLEDAI manifestations (eg, neuropsychiatric involvement, proteinuria, severe haematological features) and the Physician Global Assessment. We compared the predictive performance of MODAS/SEDAS with SLEDAI for mortality, organ damage, severe flares, hospitalisations and health-related quality of life, using receiver operating characteristics curves.ResultsAt baseline, 20% of patients met MODAS criteria and 24.6% SEDAS criteria, versus 10.5% and 3.0%, respectively, by SLEDAI. MODAS/SEDAS reclassified 19.9% of patients considered mild by SLEDAI, and 53.3% of moderate cases. MODAS/SEDAS showed modest but consistent improvement in predictive accuracy for damage (area under the curve 0.570 vs 0.550), flares (0.609 vs 0.564) and hospitalisations (0.609 vs 0.565). These definitions were associated with worse outcomes and demonstrated a dose–response relationship, although the overall predictive ability remained moderate.ConclusionMODAS and SEDAS offer an alternative framework for defining moderate and severe SLE activity, with modest but consistent improvements in predictive performance compared with SLEDAI. By integrating cSLEDAI, key severe features and physician judgement, they improve prognostic performance and support a severity-based approach to clinical management and research. Their clinical utility remains preliminary, and further external validation is required before routine implementation.Keywords: Lupus Erythematosus, Systemic; Autoimmune Diseases; Patient Reported Outcome Measures WHAT IS ALREADY KNOWN ON THIS TOPIC Accurate assessment of SLE activity is challenging, and existing tools like SLE Disease Activity Index (SLEDAI) have limitations, including low sensitivity to severe features and unvalidated activity thresholds. Accurate assessment of SLE activity is challenging, and existing tools like SLE Disease Activity Index (SLEDAI) have limitations, including low sensitivity to severe features and unvalidated activity thresholds. WHAT THIS STUDY ADDS Moderate disease activity state and severe disease activity state, two new definitions of moderate and severe SLE activity, integrate clinical SLEDAI, key severe manifestations and physician assessment, improving prediction of flares, hospitalisations and damage. Moderate disease activity state and severe disease activity state, two new definitions of moderate and severe SLE activity, integrate clinical SLEDAI, key severe manifestations and physician assessment, improving prediction of flares, hospitalisations and damage. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY These definitions provide a standardised, severity-based framework for research and patient management, although further validation is needed before routine clinical use. These definitions provide a standardised, severity-based framework for research and patient management, although further validation is needed before routine clinical use. Introduction SLE is a chronic rheumatic autoimmune disease characterised by a wide range of clinical presentations that vary from patient to patient. These manifestations can range in severity from mild or even asymptomatic cases to severe or life-threatening conditions. This variability makes the assessment and quantification of disease activity particularly challenging. Accurate categorisation of disease activity is essential for better understanding and managing the disease. The most commonly used Disease Activity Index in clinical practice is the SLE Disease Activity Index (SLEDAI).1 2 This index categorises SLE activity based on a total score: remission (0 points); mild activity (0–6 points); moderate (7–12 points); and severe (>12 points). However, these cut-off points have not been formally validated. Moreover, this categorisation has important limitations, primarily because it considers only the total score and not the severity of individual manifestations. Additional limitations of the SLEDAI include its failure to capture certain severe manifestations—such as gastrointestinal involvement or haemolytic anaemia—its inability to reflect changes within a single organ system, and the disproportionate influence of serological activity (eg, anti-double stranded DNA (anti-dsDNA) and complement levels) on the overall score. Given these limitations, incorporating the physician’s perspective through a validated tool would be a valuable complement to current assessments. In contrast, the British Isles Lupus Assessment Group-2004 Index3 is a comprehensive tool that accounts for both common and rare manifestations. It is organised by organ systems and is sensitive to changes in disease activity. However, it is more time-consuming to apply than SLEDAI because it requires multiple laboratory parameters, the use of a separate glossary to define items and the application of a specific scoring algorithm. These complexities limit its practicality in routine clinical settings. Therefore, there is a significant unmet need for simple, easy-to-use and validated definitions of SLE disease activity categories. The aim of this study is to propose a standardised definition for moderate disease activity state (MODAS) and severe disease activity state (SEDAS) in SLE using data from a large, multicentre national SLE prospective cohort, to describe the prevalence of these states and to validate the proposed definitions by analysing their impact on key SLE outcomes comparing them with the SLEDAI-based definitions. Methods Study design and patients Data for this study were gathered from the prospective phase of the RELESSER (Registro de pacientes con Lupus Eritematoso Sistémico de la Sociedad Española de Reumatología) registry (RELESSER-PROS), a multicentre, prospective cohort of patients with SLE involving 39 Spanish hospitals. The patients included in RELESSER-PROS were recruited from the cross-sectional phase of RELESSER (RELESSER-TRANS).4 RELESSER-PROS comprises a total of seven visits: data were collected annually for the first five visits and biennially for the final two. For the purposes of this study, only the first five annual visits over a 4-year period were considered. All patients enrolled in RELESSER-PROS who had completed at least two of the five annual visits were included in the analysis. Baseline visits for RELESSER-PROS took place between 2014 and 2023. The RELESSER cohort consists of patients who fulfilled at least four classification criteria of the American College of Rheumatology (ACR) for SLE or who were diagnosed with SLE by the physician and were under active follow-up. The general characteristics of the RELESSER registry, methodological aspects and variable definitions have been previously described.4 Variable definitions The definitions of MODAS and SEDAS were developed by a panel composed of six lupus experts, a methodologist and a statistician. Initially, the panel formulated conceptual definitions for both activity states, differentiating them based on the severity of clinical manifestations and the physician’s subjective assessment. The conceptual definition of MODAS and SEDAS was as follows: ‘Activity states that, if present at least once during the course of the disease, are associated with worse outcomes. Moreover, they differentiate between moderate and severe activity, the latter being associated with a higher risk of poor outcomes. Disease activity, physician’s subjective evaluation, and the presence of severe manifestations are taken into account for classification’. In the second round, the panel discussed which variables should be included in the operational definitions. Most participants supported including the SLEDAI because it is a simple, widely recognised and validated instrument. However, acknowledging the SLEDAI’s inherent limitation in capturing the severity of individual manifestations, it was agreed to also incorporate the Physician Global Assessment (PGA) to better reflect overall disease activity. Finally, the panel concluded that a list of severe manifestations should be added to account for those aspects of disease activity not fully captured by either the SLEDAI or the PGA. After reviewing the literature, an initial list of 26 candidate manifestations was compiled and evaluated using a two-round Delphi process. Panellists rated each manifestation on a 5-point Likert Scale (1=strongly disagree to 5=strongly agree) based on its clinical relevance for including in the definition of severe activity. Items with a mean score ≤4 were excluded after the first round. Nine manifestations were retained, and three additional items were debated further during the second round. It was debated if other renal domains of SLEDAI should be included as severe, and which haematological domains must be included. Consensus (≥80% agreement) was achieved on the final list which included severe manifestations such as neuropsychiatric involvement (as defined by the SLEDAI) and proteinuria (SLEDAI item, reflecting SLE renal involvement); and severe haematological manifestations not captured by the SLEDAI, namely autoimmune haemolytic anaemia, anaemia with haemoglobin <10 g/dL, microangiopathic haemolytic anaemia, thrombotic microangiopathy (thrombotic thrombocytopenic purpura) and pure red cell aplasia. Other manifestations initially considered—such as myelitis, aseptic meningitis, severe peripheral neuropathy or polyradiculopathy, lupus myocarditis, severe pericarditis or cardiac tamponade, acute lupus pneumonitis, diffuse alveolar haemorrhage, lupus-associated pulmonary hypertension, mesenteric vasculitis, lupus pancreatitis, autoimmune hepatitis attributed to lupus, necrotising cutaneous vasculitis and lupus myositis—were ultimately excluded. These manifestations were rare, not systematically recorded in the original RELESSER data set, and were judged to be adequately captured through the PGA. All participants agreed to use the clinical SLEDAI (cSLEDAI), excluding serological activity, to avoid overestimating disease activity and to emphasise clinical manifestations. A cSLEDAI score below four was classified as mild activity (non-MODAS/non-SEDAS). To distinguish between MODAS and SEDAS, the panel agreed that a cSLEDAI ≥8 would define severe activity, as this threshold corresponds to the neuropsychiatric manifestations in the SLEDAI. The PGA was included to modulate and capture situations of increased disease activity not fully reflected by the SLEDAI. The PGA was recorded on a 0–3 Visual Analogue Scale, where 0=no disease activity and 3=most severe activity, based on comprehensive evaluation of clinical and laboratory findings at each visit. The interpretation followed standard thresholds: 0=inactive, >0–1=mild, >1–2=moderate and >2–3=severe activity. These cut-offs are supported by previous validation studies.5,7 The final operational definitions of MODAS and SEDAS were therefore derived from a combination of data-driven evidence and expert consensus, integrating the cSLEDAI, the PGA and the presence of predefined severe manifestations. The proposed definitions are detailed in table 1. Table 1Proposed definitions of mild, moderate and severe disease activity statesDefinitionCriteriaMild disease activityModerate disease activity state (MODAS)Severe disease activity state (SEDAS)cSLEDAI*: not considering hypocomplementaemia nor the positivity of anti-dsDNA antibodies1≤ cSLEDAI ≤44< cSLEDAI ≤8cSLEDAI >8PGA on a 0–3 scale0< PGA ≤11< PGA ≤2PGA >2Severe SLEDAI and non-SLEDAI manifestations†Not presentNot presentPresentPresence of at least 1 of the three items for each definition.*SELENA-SLEDAI (Safety of Estrogens In Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index).†Neuropsychiatric SLE manifestations addressed by SLEDAI; proteinuria in SLEDAI; and severe haematological manifestations not included in SLEDAI: autoimmune haemolytic anaemia, with Hb <10 g/L, microangiopathic haemolytic anaemia and thrombotic thrombocytopenic purpura (TTP), pure red cell aplasia.cSLEDAI, clinical SLEDAI; PGA, Physician Global Assessment. Proposed definitions of mild, moderate and severe disease activity states Presence of at least 1 of the three items for each definition. SELENA-SLEDAI (Safety of Estrogens In Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index). Neuropsychiatric SLE manifestations addressed by SLEDAI; proteinuria in SLEDAI; and severe haematological manifestations not included in SLEDAI: autoimmune haemolytic anaemia, with Hb <10 g/L, microangiopathic haemolytic anaemia and thrombotic thrombocytopenic purpura (TTP), pure red cell aplasia. cSLEDAI, clinical SLEDAI; PGA, Physician Global Assessment. To meet the definition of either MODAS or SEDAS, a patient had to fulfil at least one of the three criteria included in the definition. A patient was classified as being in a SEDAS state if they had at least one visit meeting the SEDAS criteria. MODAS was defined as having at least one visit in the MODAS state and no visits in the SEDAS state. Patients who did not meet criteria for either MODAS or SEDAS at any visit were considered to be in a mild activity state. Outcomes collected The following outcomes were collected at each visit: mortality, damage accrual using the Systemic Lupus International Collaborating Clinics/ACR Damage Index,8 the number of severe flares according to the Selena Flare Index definition,9 health-related quality of life (HRQoL) using the lupus impact tracker (LIT)10 and hospital admissions. Hospitalisation was defined as any hospital admission, regardless of cause—whether due to lupus activity, disease-related comorbidities, infections or other reasons. The number of hospitalisations and flares between visits were also recorded. Statistical analysis A descriptive analysis was performed based on the presence of MODAS or SEDAS in at least one of the five visits, as well as according to the number of visits in which patients met criteria for either state. Subsequently, an internal validation was conducted to assess the impact of belonging to the predefined groups on various clinically relevant outcomes over time. For continuous variables, means and SD or medians and IQRs were reported, depending on the data distribution. Categorical variables were summarised using frequencies and percentages. To evaluate differences between groups regarding the outcomes of interest, appropriate statistical tests were applied based on data distribution: Student’s t-test for normally distributed continuous variables, Mann–Whitney U test for non-normally distributed variables and the χ² test for categorical variables. Receiver operating characteristics (ROC) curve analysis was used to assess the prognostic performance of SLEDAI compared with the newly proposed MODAS and SEDAS definitions in predicting key outcomes including damage accrual, hospitalisations, flares and HRQoL. A value of p<0.05 was considered statistically significant. All statistical analyses were performed using R software, V.4.0.5 (R Foundation for Statistical Computing, Vienna, Austria). Results Baseline characteristics A total of 1463 patients with SLE were included in the analysis. The majority were female (87.9%), with a mean age of 56 years (±13.5) and a mean disease duration of 14 years (±8.5) at the time of the first visit. Patients attended a mean of 4.2 (±1.2) visits over a mean follow-up period of 3.6 (±1.4) years. Detailed demographic and clinical characteristics are shown in table 2. Table 2Baseline characteristics of the cohortCohort (n=1463)Demographics Female, n (%)1286 (90%) Caucasian ethnicity, n (%)1309 (94.1%) Age, years, mean (SD) at study entry56.1 (13.6) Disease duration, years, mean (SD)14 (8.5) Age, years, mean (SD) at diagnosis33.7 (15.1) Current smoker, n (%)310 (22.1%)Clinical profile2.82 (3.85) SLEDAI-2K, mean (SD) cSLEDAI, mean (SD)2.01 (3.35) Anti-dsDNA positivity, n (%)197 (13.5%) Low complement, n (%)567 (38.8%) Physician Global Assessment, mean (SD)0.51 (0.62) Total SDI Score, mean (SD)1.42 (1.75) Organ damage present (SDI>0), n (%)921 (63.0%) LIT, mean (SD)28.2 (20.6)Medication use Prednisone, n (%)724 (49.5%) GC dose ≤5 mg483 (67.6%) >5 mg and <10 mg149 (20.8%) ≥10 mg and <30 mg61 (8.3%) ≥30 mg16 (2.24%) Antimalarial, n (%)809 (55.2%) Methotrexate, n (%)141 (9.6%) Azathioprine, n (%)179 (12.2%) Mycophenolate or mycophenolic acid, n (%)183 (12.5%) Belimumab, n (%)59 (4%) Rituximab, n (%)62 (4.2%)ACR, American College of Rheumatology; cSLEDAI, clinical SLEDAI; GC, glucocorticoids; LIT, lupus impact tracker; SDI, SLICC/ACR Damage Index; SLEDAI-2K, SLE Disease Activity Index-2000; SLICC, Systemic Lupus International Collaborating Clinics. Baseline characteristics of the cohort ACR, American College of Rheumatology; cSLEDAI, clinical SLEDAI; GC, glucocorticoids; LIT, lupus impact tracker; SDI, SLICC/ACR Damage Index; SLEDAI-2K, SLE Disease Activity Index-2000; SLICC, Systemic Lupus International Collaborating Clinics. Prevalence of disease activity states according to MODAS/SEDAS and SLEDAI At baseline, 55.36% of patients (810/1463) met criteria for mild disease activity according to the MODAS/SEDAS definitions, while 20% (293/1463) fulfilled criteria for moderate activity (MODAS) and 24.6% (360/1463) for severe activity (SEDAS) (online supplemental table 1). In comparison, according to SLEDAI-based stratification, 86.5% of patients (1265/1463) were classified as having mild activity, 10.5% (154/1463) as moderate and 3.0% (44/1463) as severe. Reclassification of disease activity Among patients with mild disease activity according to SLEDAI (n=1265), 80.1% (n=1013) remained classified as mild using the new definitions, while 10.7% (n=135) were reclassified as MODAS and 9.2% (n=117) as SEDAS. Of those with moderate SLEDAI scores (n=154), 16.9% (n=26) were reclassified as mild, 46.8% (n=72) as MODAS and 36.4% (n=56) as SEDAS. All patients classified as having severe activity according to SLEDAI (n=44) met the criteria for SEDAS under the new definitions. Overall, 19.9% of patients originally classified as having mild activity by SLEDAI were reclassified as having moderate or severe activity under the MODAS/SEDAS definitions. Additionally, 53.3% of patients with moderate SLEDAI activity were reclassified to a different category (mild or severe) by the new criteria (table 3). Table 3Classification of SLE activity according to SLEDAI and the proposed new definitions (MODAS/SEDAS)Mild SLEDAI (9–6) (n=1265)Moderate SLEDAI (>6–12) (n=154)Severe SLEDAI (>12) (n=44)Overall (n=1463)Mild disease1013 (80.1%)26 (16.9%)0 (0%)1039 (71.0%)MODAS135 (10.7%)72 (46.8%)0 (0%)207 (14.1%)SEDAS117 (9.2%)56 (36.4%)44 (100%)217 (14.8%)MODAS, moderate disease activity state; SEDAS, severe disease activity state; SLEDAI, SLE Disease Activity Index. Classification of SLE activity according to SLEDAI and the proposed new definitions (MODAS/SEDAS) MODAS, moderate disease activity state; SEDAS, severe disease activity state; SLEDAI, SLE Disease Activity Index. Predictive value for clinical outcomes The predictive performance of the proposed MODAS/SEDAS definitions was evaluated in comparison with the traditional SLEDAI-based categorisation by analysing their ability to discriminate clinically relevant outcomes through ROC curves. For organ damage accrual, the area under the curve (AUC) for MODAS/SEDAS was 0.636 (95% CI 0.603 to 0.669), outperforming the SLEDAI classification, which showed an AUC of 0.550 (95% CI 0.527 to 0.573). In terms of severe flares, MODAS/SEDAS achieved an AUC of 0.687 (95% CI 0.662 to 0.711), with better predictive accuracy than SLEDAI, which yielded an AUC of 0.564 (95% CI 0.547 to 0.581). Regarding hospitalisations, the predictive capacity of MODAS/SEDAS also exceeded that of SLEDAI, with an AUC of 0.631 (95% CI 0.605 to 0.658), compared with an AUC of 0.531 (95% CI 0.548 to 0.581) for SLEDAI. For HRQoL using LIT, we observed slight differences in the AUC. The MODAS/SEDAS categorisation achieved an AUC of 0.587 (95% CI 0.561 to 0.614) and the SLEDAI an AUC of 0.510 (95% CI 0.492 to 0.528). Although the AUC values indicate only moderate predictive ability, the consistent improvement across multiple outcomes supports the potential added value of incorporating physician assessment and severe clinical manifestations into disease activity definitions (figure 1). Receiver operating characteristics curves illustrating the relationship between sensibility (true positive fraction) and false positive fraction for the SLEDAI categorisation (red) and the new definitions for categorisation of activity (blue) with regard to organ damage. The newly proposed categorisation of disease activity offers improved discrimination of adverse outcomes when compared with conventional SLEDAI. Damage accrual (A), flares (B), hospital admissions (C) and quality of life (D). LIT, lupus impact tracker; MODAS, moderate disease activity state; SEDAS, severe disease activity state; SLEDAI, SLE Disease Activity Index. Prevalence of clinical outcomes according to the proposed disease activity definitions Patients who had at least one visit classified as MODAS or SEDAS exhibited significantly higher rates of flares, greater damage accrual, more hospital admissions and worse HRQoL (p<0.001; table 4). Table 4Outcomes, according to the presence of MODAS or SEDAS, in at least one of the five visitsMild disease activity(n=810)MODAS(n=293)SEDAS(n=360)P valueDeaths, n (%)26 (3.21)10 (3.41)7 (1.94)0.43ΔSDI (V5–V1), mean (SD)0.33 (0.68)0.615 (0.91)0.917 (1.24)<0.001Number of flares, mean (SD)0.79 (1.51)2.21 (2.49)2.43 (2.73)<0.001Admissions, mean (SD)0.58 (1.35)1.10 (1.96)1.74 (2.69)<0.001Quality of life (mean LIT), mean (SD)25.8 (20.2)35.0 (20.3)34.4 (20.1)<0.001Quality of life (highest LIT), mean (SD)34.9 (23.5)47.1 (24.1)46.8 (23.7)<0.001ACR, American College of Rheumatology; LIT, lupus impact tracker; MODAS, moderate disease activity state; SDI, SLICC/ACR Damage Index; SEDAS, severe disease activity state; SLICC, Systemic Lupus International Collaborating Clinics; ΔSDI, SDI in visit 5 (V5) minus SDI in visit 1 (V1). Outcomes, according to the presence of MODAS or SEDAS, in at least one of the five visits ACR, American College of Rheumatology; LIT, lupus impact tracker; MODAS, moderate disease activity state; SDI, SLICC/ACR Damage Index; SEDAS, severe disease activity state; SLICC, Systemic Lupus International Collaborating Clinics; ΔSDI, SDI in visit 5 (V5) minus SDI in visit 1 (V1). Prevalence of clinical outcomes according to SLEDAI-based disease activity definitions According to the SLEDAI-based classification, patients with at least one visit categorised as moderate or high disease activity experienced significantly more flares, higher damage accrual and more hospitalisations (p<0.001). However, no significant differences were observed in HRQoL or mortality between the activity categories. Comparison between different disease activity states The comparison between patients classified as SEDAS and those in the MODAS category showed that hospital admissions and damage accrual were significantly higher in the SEDAS group. Although the frequency of flares and the impact on quality of life were also greater in the SEDAS group compared with MODAS, these differences did not reach statistical significance. No differences in mortality were observed between the two groups. When MODAS and SEDAS were jointly compared with the low disease activity group, significant differences were found across all assessed outcomes—including flares, quality of life, damage accrual and hospital admissions—except for mortality (figure 2). A comparison of the risk of admissions, damage accrual, flares and quality of life between different disease activity states. Patients in MODAS have a higher risk of hospital admissions (A), damage accrual (B), number of flares (C) and worse quality of life (D) compared with patients in low disease activity state. Patients in SEDAS have a higher risk of hospital admissions (A), damage accrual (B), number of flares (C) and worse quality of life (D) compared with patients in low disease activity state. Patients in SEDAS have a higher risk of hospital admissions (A) and damage accrual (B) compared with patients in MODAS. ACR, American College of Rheumatology; LIT, lupus impact tracker; MODAS, moderate disease activity state; SDI, SLICC/ACR Damage Index; ΔSDI, SDI in visit 5 (V5) minus SDI in visit 1 (V1); SEDAS, severe disease activity state; SLICC, Systemic Lupus International Collaborating Clinics. Outcomes for different activity states based on number of visits We evaluated various outcomes, considering whether the number of visits (0, 1, 2 or 3) in different activity states correlated with poorer results. For SEDAS, we observed a direct relationship: a higher number of visits correlated with an increased number of flares, worse quality of life, greater damage and more hospital admissions. We found a near-significant difference in damage when comparing one visit versus two visits in SEDAS. However, no significant differences were found for the remaining variables when comparing one with two, or two with three visits in SEDAS (see table 5). Table 5Outcomes, according to the number of visits in SEDASNumber of visits in SEDAS0(n=1103)1(n=249)2(n=76)3(n=24)P value0 vs 1P value1 vs 2P value2 vs 3Deaths, n (%)36 (3.26%)5 (2.01%)2 (2.63%)0 (0%)NSNSNSAdmissions, mean (SD)0.72 (1.55)1.31 (1.90)2.09 (3.32)3.63 (4.00)<0.001*1.0000.281ΔSDI (V5−V1), mean (SD)0.41 (0.76)0.69 (1.03)1.30 (1.38)1.57 (1.83)0.003*0.006*1.000Number of flares, mean (SD)1.17 (1.92)2.02 (2.53)2.83 (2.80)3.71 (2.20)<0.001*0.1890.512Quality of life (mean LIT), mean (SD)28.2 (20.6)33.3 (19.6)37.2 (22.5)38.3 (16.0)0.001*1.0001.000Quality of life (highest LIT), mean (SD)38.1 (24.2)45.2 (22.9)50.2 (26.4)53.3 (19.7)0.001*1.0001.000The higher the number of visits in SEDAS, the greater the risk of hospital admissions, organ damage, flares and worse quality of life. At least one visit in either of these states can already pose a significantly increased risk for all outcomes, except for mortality.*p<0.05.ACR, American College of Rheumatology; LIT, lupus impact tracker; NS, not significant; SDI, SLICC/ACR Damage Index; SEDAS, severe disease activity state; SLICC, Systemic Lupus International Collaborating Clinics; ΔSDI, SDI in visit 5 (V5) minus SDI in visit 1 (V1). Outcomes, according to the number of visits in SEDAS The higher the number of visits in SEDAS, the greater the risk of hospital admissions, organ damage, flares and worse quality of life. At least one visit in either of these states can already pose a significantly increased risk for all outcomes, except for mortality. p<0.05. ACR, American College of Rheumatology; LIT, lupus impact tracker; NS, not significant; SDI, SLICC/ACR Damage Index; SEDAS, severe disease activity state; SLICC, Systemic Lupus International Collaborating Clinics; ΔSDI, SDI in visit 5 (V5) minus SDI in visit 1 (V1). Similarly, for MODAS, a higher number of visits in this state was associated with a greater number of flares, worse quality of life, increased damage and more hospital admissions. The number of flares showed a statistically significant difference when comparing one with two visits in MODAS, but no significant differences were found for the other outcomes (see table 6). Table 6Outcomes, according to the number of visits in MODASNumber of visits in MODAS0(n=1103)1(n=249)2(n=76)3(n=24)P value 0 vs 1P value 1 vs 2P value 2 vs 3Deaths, n (%)26 (3.26%)7 (3.27%)3 (5.17%)0 (0%)NSNSNSAdmissions, mean (SD)0.58 (1.35)1.00 (1.73)1.03 (1.83)2.14 (3.94)0.002*1.0001.000ΔSDI (V5−V1), mean (SD)0.33 (0.68)0.56 (0.80)0.61 (1.18)0.85 (0.94)0.001*1.0001.000Number of flares, mean (SD)0.79 (1.51)1.77 (2.14)3.26 (2.91)3.57 (3.61)<0.001*<0.001*1.000Quality of life (mean LIT), mean (SD)25.8 (20.2)33.1 (20.6)39.2 (18.0)37.8 (21.2)<0.001*0.3331.000Quality of life (highest LIT), mean (SD)34.9 (23.5)44.6 (24.1)51.6 (21.6)54.3 (27.0)<0.001*0.71181.000The higher the number of visits in MODAS, the greater the risk of hospital admissions, organ damage, flares and worse quality of life. At least one visit in either of these states can already pose a significantly increased risk for all outcomes, except for mortality.*p<0.05.ACR, American College of Rheumatology; LIT, lupus impact tracker; MODAS, moderate disease activity state; NS, not significant; SDI, SLICC/ACR Damage Index; SLICC, Systemic Lupus International Collaborating Clinics; ΔSDI, SDI in visit 5 (V5) minus SDI in visit 1 (V1). Outcomes, according to the number of visits in MODAS The higher the number of visits in MODAS, the greater the risk of hospital admissions, organ damage, flares and worse quality of life. At least one visit in either of these states can already pose a significantly increased risk for all outcomes, except for mortality. p<0.05. ACR, American College of Rheumatology; LIT, lupus impact tracker; MODAS, moderate disease activity state; NS, not significant; SDI, SLICC/ACR Damage Index; SLICC, Systemic Lupus International Collaborating Clinics; ΔSDI, SDI in visit 5 (V5) minus SDI in visit 1 (V1). Discussion In this national multicentre cohort study, we proposed and internally validated novel definitions for moderate (MODAS) and severe (SEDAS) disease activity in SLE. These definitions demonstrated improved capacity to identify patients at elevated risk of clinically relevant outcomes, including disease flares, organ damage accrual, hospitalisations and impaired HRQoL compared with SLEDAI-2K. The proposed framework offers a pragmatic and clinically meaningful approach that addresses limitations of the conventional SLEDAI classification and aligns with contemporary treat-to-target (T2T) strategies in SLE management.11 Consistent with previous reports, our findings highlight inherent limitations of the traditional SLEDAI instrument for that purpose. Although elevated SLEDAI scores at diagnosis predict future damage accrual, its dichotomous scoring system inadequately captures clinical nuances such as haemolytic anaemia and organ-specific disease severity.1 Our data extend these observations by demonstrating that MODAS and SEDAS, which integrate the PGA, predefined severe clinical manifestations not encompassed by SLEDAI, and specific cSLEDAI thresholds provide moderately improved discrimination of clinically meaningful outcomes. The higher AUC values for MODAS/SEDAS across several outcomes suggest a modest consistent ability for identifying patients at higher risk of adverse events. This improved predictive power underscores the value of incorporating physician judgement and a more precise assessment of severe manifestations, as opposed to relying solely on a cumulative score. However, these gains should be interpreted with caution, as the overall predictive accuracy remains moderate. Emerging disease activity indices, such as the SLE-Disease Activity Score (SLE-DAS),12 have recently provided validated numerical thresholds to define mild, moderate and severe disease activity states in SLE. Compared with SLEDAI, SLE-DAS has demonstrated superior sensitivity to clinical changes and improved performance in predicting relevant outcomes, including flares, hospitalisations and treatment response.13 14 This index incorporates continuous scoring and assigns weighted values to individual manifestations, some of them not captured by SLEDAI, thereby offering a more nuanced quantification of disease activity. While SLE-DAS functions as a continuous, quantitative instrument, the MODAS and SEDAS definitions aim to provide standardised, categorical states of moderate and severe activity that can be easily applied in clinical practice and longitudinal research. Importantly, MODAS/SEDAS integrate the PGA and predefined severe manifestations absent from SLEDAI, bridging physician judgement with objective scoring. Thus, although differing in design and purpose, both SLE-DAS and MODAS/SEDAS share the goal of improving disease characterisation beyond traditional indices. These complementary approaches underscore the ongoing evolution towards more precise and clinically meaningful assessment of disease activity in SLE. The 2023 European League Against Rheumatism recommendations emphasise long-term survival, prevention of organ damage and optimisation of HRQoL as key therapeutic objectives in SLE.15 However, the absence of validated tools to differentiate moderate from severe disease activity hinders the adoption of standardised treatment strategies tailored to disease severity. In contrast to SLEDAI, our multidimensional definitions better reflect real-world clinical judgement by incorporating the PGA as a global activity measure with established thresholds for moderate and severe activity states. MODAS and SEDAS were robustly associated with increased frequency and severity of disease flares, worse patient-reported HRQoL outcomes, and higher risks of organ damage and hospital admissions. The observed dose-response relationship between the cumulative number of visits classified as MODAS or SEDAS and adverse outcomes further supports the clinical validity of these definitions. Notably, distinguishing between moderate and severe activity states is crucial, as patients meeting SEDAS criteria exhibited significantly greater risk of damage accrual and hospitalisation compared with those with MODAS. A key finding of our study is the substantial reclassification of patients when applying the MODAS/SEDAS definitions compared with the traditional SLEDAI-based categorisation. Notably, nearly 20% of patients initially classified as having mild activity by SLEDAI were reclassified as having moderate or severe activity under the new definitions. Furthermore, over half of those with moderate SLEDAI activity were reclassified into different categories (mild or severe). This reclassification highlights the potential for SLEDAI to underestimate true disease severity, particularly in cases with significant yet uncaptured manifestations or where the PGA indicates greater concern. The inclusion of specific severe manifestations not fully captured by SLEDAI, such as certain haematological features like autoimmune haemolytic anaemia or thrombotic microangiopathy, further strengthens the clinical relevance of MODAS/SEDAS. Furthermore, our analysis of the prevalence of clinical outcomes according to the proposed MODAS/SEDAS definitions suggested a trend towards a dose–response relationship: patients in MODAS or SEDAS states experienced significantly higher rates of flares, greater damage accrual, more hospital admissions and worse HRQoL (measured by the LIT10). While SLEDAI also showed associations with flares, damage and hospitalisations, it failed to demonstrate significant differences in HRQoL between its activity categories. The ability of MODAS/SEDAS to differentiate patients based on their impact on quality of life is particularly important, as patient-reported outcomes are increasingly recognised as crucial measures of disease burden. The distinction between MODAS and SEDAS, while showing some overlap, demonstrated that hospital admissions and damage accrual were significantly higher in the SEDAS group. This suggests that the SEDAS definition effectively identifies a subset of patients with truly severe disease, warranting more intensive management. Although the differences in flares and quality of life between MODAS and SEDAS did not reach statistical significance, the trends were consistent with greater severity in the SEDAS group. It is important to note that mortality did not significantly differ across any of the activity categories, which might be attributed to the overall lower mortality rates in contemporary SLE cohorts and the relatively short follow-up period for this specific outcome in our study. The strengths of our study include its prospective, multicentre design and the comprehensive longitudinal data derived from the RELESSER cohort, which encompasses a broad spectrum of disease manifestations and outcomes. The consensus-driven development of the MODAS and SEDAS definitions enhances reproducibility and ensures clinical applicability. Nevertheless, some limitations warrant consideration. The relatively low frequency of MODAS and SEDAS observed may reflect a cohort enriched for milder disease or a limited representation of early stage patients. In addition, although MODAS and SEDAS demonstrated better discrimination of clinically relevant outcomes compared with SLEDAI, the overall predictive accuracy was only moderate. This suggests that the improvement, while consistent, remains modest and should be interpreted as preliminary, pending further validation in independent and more heterogeneous populations. In conclusion, the MODAS and SEDAS definitions provide a more nuanced and clinically informative classification of disease activity in SLE than conventional tools. These definitions, incorporating cSLEDAI, specific severe manifestations and PGA, offer improved prognostic accuracy for clinically relevant outcomes compared with traditional SLEDAI-based categorisation. Their implementation may facilitate identification of patients requiring intensified monitoring and therapeutic intervention, thereby enhancing clinical decision-making and optimising patient outcomes. Furthermore, these definitions hold promise for improving patient stratification in clinical trials and advancing T2T approaches in SLE. Supplementary material Acknowledgements The authors thank the RELESSER group collaborators for their invaluable contributions to compiling this register data. The authors also thank the employees of the Spanish Rheumatology Society Research Unit for their commitment and professionalism. The authors also thank the Spanish Foundation of Rheumatology for providing medical writing/editorial assistance during the preparation of this manuscript and for their review of its English translation (FERBT2023). Footnotes Funding: The authors declare that financial support for this study was received from the Spanish Foundation of Rheumatology. The RELESSER-PROS register is funded by GSK. AstraZeneca funds the statistical analysis of our study. These study sponsors were not involved in the study design, in the collection, analysis and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript. IA-G is supported by ACI/FER (Ayuda Facultativos Investigadores de la Federación Española de Reumatologia) (21/CONV/02/1266). JMP-R is supported by FIS/ISCIII-Fondo Europeo de Desarrollo Regional (FEDER) (grant number PI11/02857). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Consent obtained directly from patient(s). Ethics approval: This study involves human participants and was approved by Hospital Dr. Negrin Ethics Committee. Participants gave informed consent to participate in the study before taking part. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Data availability statement Data are available upon reasonable request. References Associated Data Supplementary Materials Data Availability Statement Data are available upon reasonable request.